Hella Sand looked at rigid v deformable reg for lung #reirradiation. Both performed well, with good inter-centre consistency, but less variation for DIR, especially for cumulative max dose. Results have driven recommendations in the CURE Lung reRT trial #radonc #medphys #ESTRO25
Isak Wahlsted led a national study of dose accumulation for #reirradiation: 8 diverse cases evaluated in all Danish RT centres
Image reg was consistent & high quality; but differences in a/b & tissue recovery gave substantial intercentre variation in cumulative dose #medphys #radonc #ESTRO25
Inter-centre variation in image registration for #reirradiation from DK: Two great studies from collaborators presented at #ESTRO25
Conclusions: Image registration-based dose accum for reRT is feasible. For lung, DIR is better than RIR. Radiobio factors largest source of variation #radonc #medphys
Fantastic talk by Corinne Faivre-Finn on women in radiation oncology and the changes which needs to be made. Congratulations with the award.
Impressive OS for reRT in lung cancer presented by Marianne Knap from Aarhus University Hospital
I am so excited to get all the work on reirradiation started and looking forward for the collaboration with people in the group and all others being interested
I am so excited to get all the work on reirradiation started and looking forward for the collaboration with people in the group and all others being interested
Sarah Eckholdt presenting the robustness results of the European phase III PROTECT trial showing very good compliance with the trial requirements on dose delivery
Sarah Eckholdt presenting the robustness results of the European phase III PROTECT trial showing very good compliance with the trial requirements on dose delivery
For even more #reirradiation highlights and discussion, join the dedicated conference WhatsApp group!
#ESTRO25 #medphys #radonc
Can you dose escalate locally advanced NSCLC to 88+ Gy without excess toxicity?
Yes! If you use heterogeneous dose escalation & careful QA.
6-month toxicity data from the Scandinavian phase III dose escalation NARLAL2 trial now online in JCO:
ascopubs.org/doi/abs/10.1...
#radonc
Absolutely no difference in toxicity profiles between 66Gy and dose escalation; even when considering lower grade events or time profiles
(Major caveat: we’re only reporting toxicity up to 6 months at this point - but we’ve not seen any signals in the late toxicity so far either)
The first Italian PROTECT patient has been treated with protons at the Trento Proton Therapy Centre. Read more on why Trento participates in the PROTECT study, protonterapia.provincia.tn.it/eng/News-and...
Fuld day workshop on reRT with participation from all Danish RT clinics. The aim is to set up a Danisk registration protokol for reRT
Overview of the PROTECT RTQA program
The PROTECT RTQA paper has been published: medicaljournalssweden.se/actaoncologi...
